LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC reduced its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,601 shares of the medical instruments supplier’s stock after selling 549 shares during the quarter. Jackson Creek Investment Advisors LLC owned about 0.08% of LeMaitre Vascular worth $1,622,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its holdings in shares of LeMaitre Vascular by 48.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock worth $1,227,000 after purchasing an additional 4,330 shares during the last quarter. Townsquare Capital LLC boosted its position in shares of LeMaitre Vascular by 38.0% in the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after purchasing an additional 13,210 shares during the period. Barclays PLC grew its stake in LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after buying an additional 29,180 shares during the last quarter. Compass Planning Associates Inc acquired a new position in LeMaitre Vascular during the fourth quarter worth approximately $567,000. Finally, Charles Schwab Investment Management Inc. increased its position in LeMaitre Vascular by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after buying an additional 11,395 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Down 5.2 %

Shares of LMAT opened at $82.49 on Friday. The stock’s 50 day moving average is $96.52 and its two-hundred day moving average is $94.86. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58. The firm has a market capitalization of $1.85 billion, a PE ratio of 45.08, a P/E/G ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.49. The firm had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Thursday, March 13th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

Analysts Set New Price Targets

LMAT has been the topic of a number of research reports. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Lake Street Capital raised their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.